Skye Bioscience
SAN DIEGO, California, United States · Biotechnology, Healthcare
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. With a focus on obesity and ocular indications, Skye is dedicated to unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibro
Key facts
- Headquarters
- SAN DIEGO, California, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare
- Status
- Public (SKYE)
- Website
- skyebioscience.com
- Company page
Recent activity at Skye Bioscience
- : Skye Bioscience Announces Resignation of Chief Financial Officer John P. Sharp
- : SEC 8-K (1.02): On September 8, 2026, Skye Bioscience, Inc. terminated the Master Services Agreement with Lohman & Associates, Inc. due to the resignation of John P. Sharp, the Chief Financial Officer. The termination is effective immediately as of the same date. This action reflects a significant change in the company's operational agreements following a key leadership departure. The Master Services Agreement was originally dated March 31, 2026, indicating that it was a relatively recent arrangement that is now being dissolved.
- : SEC 8-K (1.01): Skye Bioscience, Inc. entered into a binding Securities Purchase Agreement with Redmile Biopharma Investments III, L.P. on August 21, 2026, under which the Company will sell up to $22,000,000 worth of common and non-voting shares. This agreement is part of an overall transaction framework established in conjunction with a previous Transaction Agreement with Redx Pharma Limited and a PIPE Securities Purchase Agreement. The structure of the deal includes conditions where the sale amount may be adjusted based on prior equity funding, specifically if the total equity proceeds from related deals exceed certain thresholds such as $125,000,000. This strategic engagement aims to enhance the Company's financing capabilities while managing equity levels effectively.
- : SEC 8-K (3.01): On August 18, 2026, Skye Bioscience, Inc. received a notification from the Nasdaq Listing Qualifications Department indicating non-compliance with Nasdaq Listing Rule 5550(b)(1) due to insufficient stockholders' equity, which stood at ($497,307). This failure to meet the minimum stockholders’ equity requirement of $2,500,000 highlights potential financial distress for the company. Although this notice does not immediately affect the listing or trading of Skye’s common stock on the Nasdaq Capital Market, it signals a need for the company to address its financial position to maintain compliance in the future.
- : SEC 8-K (5.02):
- : SEC 8-K (8.01): On June 18, 2026, Skye Bioscience, Inc. received approval from Nasdaq to transfer its common stock listing from the Nasdaq Global Market, which requires a minimum stockholders' equity of $10,000,000, to the Nasdaq Capital Market, which has a lower requirement of $3,000,000. This decision was prompted by the Company’s reported stockholders' equity of $9,011,804 in its Quarterly Report for the quarter ended March 31, 2026. The transfer will take effect with the market opening on June 23, 2026, and the existing ticker symbol 'SKYE' will remain unchanged. The Company faces ongoing challenges regarding compliance with the Minimum Bid Price Requirement but has a 180-day period until September 14, 2026, to remedy this situation.
- : SEC 8-K (5.02): On March 31, 2026, Skye Bioscience, Inc. approved a stock option repricing for all outstanding stock options held by current full-time employees, including executive officers, reducing the exercise price to $0.6150 per share. This decision was made by the Compensation Committee of the Board to retain and motivate key employees, avoiding further dilution or cash expenditures. The total shares under the repriced options amount to 2,420,978, previously having exercise prices ranging from $1.055 to $14.56. Additionally, John P. Sharp was appointed as the Chief Financial Officer of Skye Bioscience, effective immediately on the same date, bringing over 30 years of experience in the biopharmaceutical industry.
- : Skye Bioscience Announces Departure of CFO Kaitlyn Arsenault
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On February 2, 2026, Skye Bioscience, Inc. issued a press release announcing interim results from the combination cohort of its Phase 2a extension study of nimacimab. This filing is a Regulation FD Disclosure intended to inform investors of the important developments in the clinical trial, highlighting key findings from the study. The interim results will provide insights into the efficacy and safety profile of nimacimab, potentially impacting future clinical development and investor interest. The press release is included as Exhibit 99.1, with an updated Investor Presentation as Exhibit 99.2, which will also be available on the Company’s website.
Skye Bioscience funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2024 | Venture | $40.0M |
| Feb 2024 | Venture | $50.0M |
| Aug 2023 | Venture | $62.3M |
| Nov 2017 | Seed | $2.0M |
| Jan 2017 | Seed | $1.2M |
Leadership
- Punit Dhillon, Chief Executive Officer & Director
- Douglas Ingram, Director
- Thomas George, Director
- Gerald McLaughlin, Director
- Brian Murphy, Executive Officer, Director
- Cosmas Lykos, Executive Officer, Director
Verified email and direct lines for Skye Bioscience’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Skye Bioscience files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Skye Bioscience in the news
- Skye Bioscience Treats First Patient in Nimacimab - GlobeNewswire (Apr 02, 2026)
- Skye-Redx Deal Puts Crohn’s Treatment Candidate on Path to Phase 2 - Stock Titan (Aug 14, 2026)
- Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - PR Newswire (Jan 05, 2026)
- Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update - GlobeNewswire (May 11, 2026)
- Skye Bioscience, Inc. (SKYE) Company Information - Simply Wall St (Apr 12, 2024)
- Skye Bioscience Announces Participation in February Conferences - The Manila Times (Feb 04, 2025)
- Skye Bioscience to Participate in Upcoming Investment and Medical Conferences - GlobeNewswire (Aug 21, 2025)
- Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025 - GlobeNewswire (Jul 30, 2025)
Companies similar to Skye Bioscience
- Oruka Therapeutics · Biotechnology, Healthcare
- ORTHALIGN INC · Biotechnology, Healthcare
- Catalent Pharma Solutions · Biotechnology, Healthcare
- Starton Therapeutics · Biotechnology, Healthcare
- Metabolon · Biotechnology, Healthcare
About Skye Bioscience: questions and answers
What does Skye Bioscience do?
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. With a focus on obesity and ocular indications, Skye is dedicated to unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibro
Where is Skye Bioscience headquartered?
Skye Bioscience is headquartered in SAN DIEGO, California, United States.
Has Skye Bioscience raised funding?
Yes. Fundz has recorded 5 funding events for Skye Bioscience. The most recent, $40.0M, was in Mar 2024.
Who leads Skye Bioscience?
Punit Dhillon is a Chief Executive Officer & Director at Skye Bioscience.
What is the latest news on Skye Bioscience?
On Sep 11, 2026, Skye Bioscience Announces Resignation of Chief Financial Officer John P. Sharp
Is Skye Bioscience a public company?
Yes. Skye Bioscience is publicly traded under the ticker SKYE.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy